Objective:

To highlight the expanding role of innate lymphoid cells (ILCs) in cancer progression and therapeutic outcomes.

Approach:

Key Findings:

• ILT2 is upregulated on CD56dim NK cells in HCC, linked to impaired cytotoxicity.
• IL-13-producing ILC1-like CD56dim NK cells may contribute to tumor progression in HNSCC.
• CD56bright NK cells in bladder tumors are associated with favorable patient prognosis.

Interpretation:

Limitations:

• The need for deeper understanding of ILC phenotype and regulatory mechanisms.
• Potential variability in ILC responses based on tumor type and stage.

Conclusion:

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.